107 Dose-finding and safety study of an oncolytic polio/rhinovirus recombinant against recurrent glioblastoma.
Current therapies for glioblastoma are limited by ineffective delivery beyond the blood-brain barrier, limited diffusion of regionally-delivered macromolecules, and lack of tumor specificity. Sustained direct intracerebral infusion at slow flow rates [convection-enhanced delivery (CED)] can overcome delivery barriers. PVSRIPO is the live attenuated, oral (SABIN) serotype 1 poliovirus vaccine containing a heterologous internal ribosomal entry site stemming from human rhinovirus type 2. PVSRIPO recognizes nectin-like molecule-5, an oncofetal cell adhesion molecule and tumor antigen widely expressed ectopically in malignancy. We are reporting results of an ongoing phase I study evaluating PVSRIPO via CED delivery.
Sampson, JH; Desjardins, A; Peters, KB; Ranjan, T; Vlahovic, G; Lally-Goss, D; Threatt, S; Herndon, J; Friedman, AH; Friedman, H; Bigner, D; Gromeier, M
Volume / Issue
Start / End Page
Electronic International Standard Serial Number (EISSN)
Digital Object Identifier (DOI)